BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 17382026)

  • 1. Epidermal growth factor receptor inhibitors plus chemotherapy in non-small-cell lung cancer: biologic rationale for combination strategies.
    Gandara DR; Davies AM; Gautschi O; Mack PC; Lau DH; Lara PN; Hirsch FR
    Clin Lung Cancer; 2007 Feb; 8 Suppl 2():S61-7. PubMed ID: 17382026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor tyrosine kinase inhibitors: application in non-small cell lung cancer.
    Thomas M
    Cancer Nurs; 2003 Dec; 26(6 Suppl):21S-25S. PubMed ID: 15025409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.
    Ready N
    Semin Oncol; 2005 Apr; 32(2 Suppl 3):S35-41. PubMed ID: 16015534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual targeting of the vascular endothelial growth factor and epidermal growth factor receptor pathways: rationale and clinical applications for non-small-cell lung cancer.
    Byers LA; Heymach JV
    Clin Lung Cancer; 2007 Feb; 8 Suppl 2():S79-85. PubMed ID: 17382029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrating epidermal growth factor receptor-targeted therapies into platinum-based chemotherapy regimens for newly diagnosed non-small-cell lung cancer.
    Pirker R; Minar W; Filipits M
    Clin Lung Cancer; 2008; 9 Suppl 3():S109-15. PubMed ID: 19419924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BEVERLY: Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non-Small-Cell Lung Cancer.
    Gridelli C; Rossi A; Ciardiello F; De Marinis F; Crinò L; Morabito A; Morgillo F; Montanino A; Daniele G; Piccirillo MC; Normanno N; Gallo C; Perrone F
    Clin Lung Cancer; 2016 Sep; 17(5):461-465. PubMed ID: 27209164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining anti-Epidermal Growth Factor Receptor (EGFR) and anti-angiogenic strategies in advanced NSCLC: we should have known better….
    Di Maio M; Morabito A; Piccirillo MC; Daniele G; Giordano P; Costanzo R; Sandomenico C; Montanino A; Rocco G; Perrone F
    Curr Pharm Des; 2014; 20(24):3901-13. PubMed ID: 24191956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biologically targeted treatment of non-small-cell lung cancer: focus on epidermal growth factor receptor.
    Natale RB
    Clin Lung Cancer; 2003 Sep; 5 Suppl 1():S11-7. PubMed ID: 14641989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of tyrosine kinase inhibitors in lung cancer.
    Ansari J; Palmer DH; Rea DW; Hussain SA
    Anticancer Agents Med Chem; 2009 Jun; 9(5):569-75. PubMed ID: 19519298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Select clinical trials of erlotinib (OSI-774) in non-small-cell lung cancer with emphasis on phase III outcomes.
    Fuster LM; Sandler AB
    Clin Lung Cancer; 2004 Dec; 6 Suppl 1():S24-9. PubMed ID: 15638954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New insights in drug development for the non-small cell lung cancer therapy.
    Gridelli C; Rossi A; Maione P; Ferrara C; Del Gaizo F; Guerriero C; Nicolella D; Palazzolo G; Falanga M; Colantuoni G
    Front Biosci; 2008 May; 13():5108-19. PubMed ID: 18508573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of EGFR inhibitors in nonsmall cell lung cancer.
    Ciardiello F; De Vita F; Orditura M; Tortora G
    Curr Opin Oncol; 2004 Mar; 16(2):130-5. PubMed ID: 15075904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Review of Regimens Combining Pemetrexed With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the Treatment of Advanced Nonsquamous Non-Small-Cell Lung Cancer.
    Yang JC; Mok T; Han B; Orlando M; Puri T; Park K
    Clin Lung Cancer; 2018 Jan; 19(1):27-34. PubMed ID: 28743421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overview of the current status of human epidermal growth factor receptor inhibitors in lung cancer.
    Herbst RS; Sandler AB
    Clin Lung Cancer; 2004 Dec; 6 Suppl 1():S7-S19. PubMed ID: 15638959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of epidermal growth factor receptor in advanced non-small cell lung carcinoma.
    Jänne PA
    Ann Med; 2003; 35(7):450-7. PubMed ID: 14649327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations.
    Cheng Y; Murakami H; Yang PC; He J; Nakagawa K; Kang JH; Kim JH; Wang X; Enatsu S; Puri T; Orlando M; Yang JC
    J Clin Oncol; 2016 Sep; 34(27):3258-66. PubMed ID: 27507876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Randomized Phase II Study Comparing Nivolumab With Carboplatin-Pemetrexed for Patients With EGFR Mutation-Positive Nonsquamous Non-Small-Cell Lung Cancer Who Acquire Resistance to Tyrosine Kinase Inhibitors Not Due to a Secondary T790M Mutation: Rationale and Protocol Design for the WJOG8515L Study.
    Hayashi H; Chiba Y; Sakai K; Fujita T; Yoshioka H; Sakai D; Kitagawa C; Naito T; Takeda K; Okamoto I; Mitsudomi T; Kawakami Y; Nishio K; Nakamura S; Yamamoto N; Nakagawa K
    Clin Lung Cancer; 2017 Nov; 18(6):719-723. PubMed ID: 28623122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted therapy for the treatment of non-small cell lung cancer: focus on inhibition of epidermal growth factor receptor.
    Harichand-Herdt S; Ramalingam SS
    Semin Thorac Cardiovasc Surg; 2008; 20(3):217-23. PubMed ID: 19038731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.